Logo

CTXR

Citius Pharmaceuticals, Inc.

CTXR

Citius Pharmaceuticals, Inc. • NASDAQ
$1.44 ▲ 2.86% (+0.04)
Market Cap $16.09 M
52w High $5.95
52w Low $0.65
Dividend Yield 0%
P/E -0.3
Volume 539.28K
Outstanding Shares 11.17M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $8.747M ▼ $-8.79M ▲ 0% $-0.8 ▲ $-8.726M ▲
Q2-2025 $0 $11.261M ▲ $-10.917M ▼ 0% $-1.27 ▲ $-11.191M ▼
Q1-2025 $0 ▼ $10.04M ▼ $-9.768M ▲ 0% ▲ $-1.3 ▲ $-9.985M ▲
Q4-2024 $155.926K ▲ $11.05M ▲ $-10.79M ▼ -6.92K% ▼ $-1.59 ▼ $-10.997M ▼
Q3-2024 $0 $10.634M $-10.573M 0% $-1.57 $-10.581M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $6.089M ▲ $127.677M ▲ $60.116M ▲ $65.059M ▲
Q2-2025 $26.41K ▼ $121.481M ▲ $57.906M ▲ $60.659M ▼
Q1-2025 $1.1M ▼ $120.703M ▲ $51.784M ▲ $65.408M ▼
Q4-2024 $3.252M ▼ $116.652M ▲ $42.55M ▲ $70.077M ▼
Q3-2024 $17.911M $97.091M $10.806M $85.684M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-9.204M ▲ $-5.407M ▼ $0 $11.469M ▲ $6.063M ▲ $-5.407M ▼
Q2-2025 $-11.512M ▼ $-4.539M ▲ $0 $3.466M ▲ $-1.074M ▲ $-4.539M ▲
Q1-2025 $-10.281M ▲ $-4.726M ▲ $0 ▲ $2.574M ▲ $-2.152M ▲ $-4.726M ▲
Q4-2024 $-11.077M ▼ $-5.913M ▲ $-5M ▼ $-3.747M ▼ $-14.659M ▼ $-5.913M ▲
Q3-2024 $-10.573M $-8.367M $0 $13.719M $5.352M $-8.367M

Five-Year Company Overview

Income Statement

Income Statement Citius is still essentially a pre‑revenue biotech. Over the past several years it has reported no meaningful product sales and has run a steady operating loss each year. Losses have been relatively consistent rather than sharply escalating, but the business is clearly in a spending phase, investing in development and commercialization rather than generating income. The repeated negative earnings per share also reflect dilution over time as the company has funded itself through equity.

Balance Sheet

Balance Sheet The balance sheet is small in scale and typical of a clinical‑stage biotech. Assets are modest, with cash having trended down in recent years as funds are used to cover operating losses. There is no reported debt, which reduces financial leverage risk but also means equity is the primary funding tool. Shareholders’ equity remains positive but has been gradually eroded by continued losses. Overall, the company appears thinly capitalized and likely dependent on future capital raises, partnerships, or licensing income.

Cash Flow

Cash Flow Cash flow from operations has been consistently negative, reflecting ongoing R&D, clinical, and overhead spending without offsetting revenue. The level of cash burn has been fairly stable year to year, suggesting disciplined but persistent consumption of cash. Capital spending is minimal, so free cash flow is driven almost entirely by operating losses rather than large investments in physical assets. This profile underscores the need for external financing to sustain programs until meaningful product revenue arrives.

Competitive Edge

Competitive Edge Citius competes by focusing on narrow but important medical niches with limited treatment options rather than crowded mass markets. Its lead assets aim to become category‑defining products: Mino‑Lok as a catheter‑salvage therapy with no direct approved rival, LYMPHIR as a targeted therapy for a rare lymphoma, and Halo‑Lido potentially as the first prescription hemorrhoid treatment. Patent protection, regulatory designations, and potential exclusivity periods support its moat. The main competitive challenges are its small scale, the need to build or partner for commercial infrastructure, and convincing clinicians and payers to adopt new therapies in areas where current practices are entrenched.

Innovation and R&D

Innovation and R&D Innovation is the core of the Citius story. The company has assembled a portfolio that spans late‑stage antibiotics, oncology, supportive care, and next‑generation cell therapies. One product (LYMPHIR) is already FDA‑approved, Mino‑Lok has completed a pivotal Phase 3 trial, and Halo‑Lido has encouraging mid‑stage data, while NoveCite’s stem‑cell platform and Mino‑Wrap are earlier bets. This mix provides multiple shots on goal but also exposes the company to scientific, regulatory, and execution risk at each stage. Success depends not only on approvals but on effective manufacturing, commercialization, and continued clinical differentiation versus emerging competitors.

Summary

Citius is a small, development‑heavy biotech transitioning toward commercialization. Financially, it has no material revenue yet, recurring losses, ongoing cash burn, and a lean balance sheet with no debt but limited resources, pointing to a continued reliance on external financing. Strategically, its strength lies in a focused pipeline targeting unmet needs, with one approved product and several late‑ or mid‑stage assets that could transform its revenue profile if they launch successfully. The overall picture is a high‑risk, high‑uncertainty setup typical of late‑stage biopharma, where future outcomes hinge on regulatory milestones, market uptake, and access to sufficient capital to bridge the gap from development to sustainable commercial operations.

NEWS

November 25, 2025 · 8:00 AM UTC

Citius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual Meeting

Read more

November 21, 2025 · 8:37 AM UTC

Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration

Read more

October 21, 2025 · 4:30 PM UTC

Citius Pharmaceuticals Announces the Closing of Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules

Read more

October 21, 2025 · 8:00 AM UTC

Citius Pharmaceuticals Announces a Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules

Read more

October 17, 2025 · 5:00 PM UTC

Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences

Read more